|
Nov 7
|
Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024
|
|
Nov 5
|
Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update
|
|
Sep 3
|
Agenus to Participate in September Investor Conferences
|
|
Jul 26
|
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical
|
|
Jul 26
|
Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update
|
|
Jul 12
|
IGM Biosciences (IGMS) Soars 32.7%: Is Further Upside Left in the Stock?
|
|
Jun 28
|
Sector Update: Health Care Stocks Edge Higher in Afternoon Trading
|
|
Jun 28
|
Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference
|
|
Jun 27
|
Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies
|
|
Jun 13
|
Nature Medicine Reports Agenus’ Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50
|
|
May 8
|
Agenus Inc. (NASDAQ:AGEN) Q1 2024 Earnings Call Transcript
|
|
May 8
|
Agenus First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
|
May 8
|
Agenus Inc (AGEN) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ...
|
|
May 7
|
Agenus (AGEN) Q1 2024 Earnings Call Transcript
|
|
May 7
|
Agenus (AGEN) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 7
|
Agenus Inc (AGEN) Q1 2024 Earnings: Misses Revenue and EPS Estimates Amid Strategic Developments
|
|
May 7
|
Agenus Reports First Quarter 2024 Results
|
|
May 7
|
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
|
|
May 1
|
Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement
|
|
Apr 28
|
Up 40%: Is This Red-Hot Growth Stock Still a Buy?
|